Phio Pharmaceuticals Corp (PHIO)

[sabaidii2]

RXI (and virtually all R&D biotechs), doesn't have money to do Phase 3 testing because it costs big bucks. Talking about FDA approval is the province of Big Pharma; not small under-funded endeavors.

Realistically, RXI's path to continued existence lies with the cosmeceuticals. Maybe also with Samcyprone if the Phase 2 results are impressive.
Dermal scarring? less so.
Retinal scarring? Way, way too early in its testing.